首页 | 本学科首页   官方微博 | 高级检索  
     


Early breast cancer following treatment of myelodysplastic syndrome: Report of a case
Authors:Tsuyoshi Kataoka  Takayuki Kadoya  Keiji Sugi  Mamoru Takahashi  Takahiko Gotoh  Rumi Haruta  Toshimasa Asahara  Kiyohiko Dohi  Masayuki Nishiki  Koji Arihiro
Affiliation:(1) Second Department of Surgery, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, 734-8551 Hiroshima, Japan;(2) Institute of Health Sciences, Hiroshima University School of Medicine, Japan;(3) Second Department of Pathology, Hiroshima University School of Medicine, Japan
Abstract:A 45-year-old woman was admitted to our hospital complaining of a mass in her left breast. She had previously been diagnosed with myelodysplastic syndrome (MDS), a type of refractory anemia, based on bone marrow findings and chromosome analysis. She received a preoperative transfusion of fresh packed platelets and a recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection. Left partial mastectomy and axillary lymph nodes dissection were performed to treat early breast cancer. Postoperatively, prophylactic radiotherapy of the residual breast and administration of medroxyprogesterone acetate (MPA) were performed because the tumor tissue was positive for progesterone receptors. She has remained clinically stable, with no evidence of recurrence, for more than three years to date. We report a rare case of breast cancer with MDS, treated with breast-conserving therapy. The strategy of pre- or postoperative platelet transfusion, rhG-CSF injections, and hormonal therapy (AAPA) appears to be suitable treatment for progesterone receptor (PgR)-positive breast cancer patients with AADS.
Keywords:Myelodysplastic syndrome  Breast cancer  Breast-conserving therapy  Medroxyprogesterone acetate
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号